SCHEMBL2447355

SCHEMBL2447355

O=C(O)O[C@H]1CCOC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1691304 1.00
SCHEMBL2011670 1.00
SCHEMBL4691011 0.87 EPHX1 (0.34)
SCHEMBL1023585 0.86 KAT2B (0.39)
SCHEMBL25394555 0.84 CTSL (0.38)
Hydrochloric Acid SCHEMBL3966982 0.84 KAT2B (0.38)
SCHEMBL3999275 0.84 CTSL (0.38)
SCHEMBL3839876 0.84 CTSL (0.38)
SCHEMBL7340651 0.83 CTSL (0.33)
SCHEMBL2286907 0.82

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1761542-B1 OCTAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES AN THEIR USE AS ANTIVIRAL AGENTS HOFFMANN LA ROCHE (CH) 2008-01-02 EP claimed
CN-118900839-A Antiviral compounds and methods of making and using the same 吉利德科学公司 2024-11-05 CN disclosed
US-11844776-B2 Composition for treatment and/or prevention of peripheral nerve disorder OSAKA CITY UNIVERSITY (JP) 2023-12-19 US disclosed
US-20230382940-A1 ANTIVIRAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME GILEAD SCIENCES, INC. 2023-11-30 US disclosed
WO-2023168254-A1 ANTIVIRAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME GILEAD SCIENCES, INC. (US) 2023-09-07 WO disclosed
US-20190314320-A1 COMPOSITION FOR TREATMENT AND/OR PREVENTION OF PERIPHERAL NERVE DISORDER OSAKA CITY UNIVERSITY (JP) 2019-10-17 US disclosed
EP-3466421-A1 COMPOSITION FOR TREATMENT AND/OR PREVENTION OF PERIPHERAL NERVE DISORDER Osaka City University (JP) 2019-04-10 EP disclosed
EP-2647386-B1 LISSENCEPHALY THERAPEUTIC AGENT UNIV OSAKA CITY (JP) 2018-09-05 EP disclosed
US-9539298-B2 Lissencephaly therapeutic agent OSAKA CITY UNIVERSITY (JP) 2017-01-10 US disclosed
US-20160250276-A1 LISSENCEPHALY THERAPEUTIC AGENT OSAKA CITY UNIVERSITY (JP) 2016-09-01 US disclosed
US-20040127488-A1 Inhibitors of aspartyl protease VERTEX PHARMACEUTICALS INCORPORATED 2004-07-01 US disclosed
US-6617350-B2 Sulfonamides which are aspartyl protease inhibitors; well suited for inhibiting HIV-1 and HIV-2 protease activity VERTEX PHARMACEUTICALS INCORPORATED 2003-09-09 US disclosed
US-6573388-B1 Synthetic intermediates for the synthesis of HIV protease inhibitors and oligopeptide mimetics SAMCHULLY PHARM. CO., LTD. (KR) 2003-06-03 US disclosed
US-20020198388-A1 Inhibitors of aspartyl protease VERTEX PHARMACEUTICALS INCORPORATED 2002-12-26 US disclosed
EP-1159278-A2 INHIBITORS OF ASPARTYL PROTEASE Vertex Pharmaceuticals Incorporated (US) 2001-12-05 EP disclosed
US-6319946-B1 BENZODIOXOLYLSULFONAMIDES; INHIBITING HIV-1 AND HIV-2 PROTEASE ACTIVITY VERTEX PHARMACEUTICALS INCORPORATED 2001-11-20 US disclosed
WO-2001012599-A1 NEW ETHYLAZIRIDINE DERIVATIVES AND THEIR PREPARATION METHODS SAMCHULLY PHARM CO., LTD. (KR) 2001-02-22 WO disclosed
WO-2000047551-A2 INHIBITORS OF ASPARTYL PROTEASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2000-08-17 WO disclosed
EP-1001969-A1 PEPTIDOMIMETIC DERIVATIVES SUICIDAL INHIBITORS OF THE HIV PROLIFERATION ZAMBON GROUP S.p.A. (IT) 2000-05-24 EP disclosed
WO-1999001470-A2 PEPTIDOMIMETIC DERIVATIVES SUICIDAL INHIBITORS OF THE HIV PROLIFERATION ZAMBON GROUP S.P.A. (IT) 1999-01-14 WO disclosed